for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Blueprint Medicines Corp

BPMC.OQ

Latest Trade

78.48USD

Change

3.92(+5.26%)

Volume

193,785

Today's Range

74.30

 - 

78.71

52 Week Range

45.15

 - 

102.37

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
74.56
Open
74.84
Volume
193,785
3M AVG Volume
10.04
Today's High
78.71
Today's Low
74.30
52 Week High
102.37
52 Week Low
45.15
Shares Out (MIL)
49.20
Market Cap (MIL)
3,861.38
Forward P/E
-10.13
Dividend (Yield %)
--

Next Event

Blueprint Medicines Corp to Host Investor Event and Webcast

Latest Developments

More

Blueprint Medicines Outlines Precision Therapy Research Vision

Blueprint Medicines Announces FDA Intent To Split Avapritinib New Drug Application Into Separate Submissions For PDGFRA Exon 18 Mutant GIST And Fourth-Line GIST

Ipsen And Blueprint Medicines Sign Exclusive Global License Agreement For BLU-782

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Blueprint Medicines Corp

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

Industry

Biotechnology & Drugs

Contact Info

45 Sidney St

+1.617.3747580

http://www.blueprintmedicines.com/

Executive Leadership

Daniel S. Lynch

Chairman of the Board

Jeffrey W. Albers

President, Chief Executive Officer, Director

Michael Landsittel

Chief Financial Officer

Kathryn Haviland

Chief Operating Officer

Christopher K. Murray

Senior Vice President, Technical Operations

Key Stats

1.64 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.640

2017

-3.920

2018

-5.390

2019(E)

-7.585
Price To Earnings (TTM)
--
Price To Sales (TTM)
241.16
Price To Book (MRQ)
7.47
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-60.60
Return on Equity (TTM)
-53.82

Latest News

Latest News

Loxo Oncology's targeted RET drug shows promise in early trial

An experimental Loxo Oncology Inc drug that targets cancers with mistakes in the RET gene led to tumor shrinkage in nearly 70 percent of patients regardless of where their cancer originated, according to preliminary data from a small study released on Wednesday.

BRIEF-Blueprint Medicines Q1 Loss Per Share $1.29

* BLUEPRINT MEDICINES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Blueprint Medicines Q4 Loss Per Share $1.23

* BLUEPRINT MEDICINES REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Blueprint Medicines Prices Public Offering Of 3.70 Mln Shares At $81.00/Share

* BLUEPRINT MEDICINES ANNOUNCES PRICING OF PUBLIC OFFERING OF SHARES OF COMMON STOCK

BRIEF-Blueprint Medicines Announces Proposed Public Offering Of Shares Of Common Stock

* BLUEPRINT MEDICINES ANNOUNCES PROPOSED PUBLIC OFFERING OF SHARES OF COMMON STOCK

BRIEF-Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285

* Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285 in patients with advanced gastrointestinal stromal tumors showing strengthened clinical activity across spectrum of kit and pdgfrα genotypes

BRIEF-Thermo Fisher enters agreement with Blueprint Medicines​

* Thermo Fisher Scientific Inc - expanded development of Oncomine Dx Target Test by entering into an agreement with Blueprint Medicines Corporation

BRIEF-Blueprint Medicines Q3 loss per share $0.96

* Blueprint Medicines reports third quarter 2017 financial results

BRIEF-Blueprint Medicines Q2 loss per share $0.86

* Blueprint Medicines reports second quarter 2017 financial results

BRIEF-Blueprint Medicines to evaluate advance disease discovery program opportunities

* Blueprint Medicines to evaluate opportunities to advance rare disease discovery program in fibrodysplasia ossificans progressiva following discontinuation of collaboration with Alexion

BRIEF-Blueprint Medicines announces new phase 1 clinical data for Blu-285

* Blueprint medicines announces new phase 1 clinical data for Blu-285 in advanced gastrointestinal stromal tumors and plans to pursue expedited development in patients with a pdgfrα d842v mutation

BRIEF-Blueprint Medicines Q1 loss per share $0.84

* Blueprint Medicines reports first quarter 2017 financial results

BRIEF-Blueprint Medicines announces pricing of public offering of shares of common stock

* Blueprint Medicines announces pricing of public offering of shares of common stock

BRIEF-Blueprint Medicines announces public offering of shares of common stock

* Blueprint Medicines announces proposed public offering of shares of common stock

BRIEF-Blueprint Medicines enrolls first patient in BLU-667 Phase 1 clinical trial

* Blueprint Medicines announces enrollment of first patient in Phase 1 clinical trial for BLU-667 Source text for Eikon: Further company coverage:

BRIEF-Blueprint Medicines files for potential mixed shelf offering

* Blueprint Medicines Corp files for potential mixed shelf offering; size not disclosed Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up